



Dear Participating Pharmaceutical Manufacturer:

In May 2026, the Pharmacy & Therapeutics (P&T) Committees of the states participating in the Prime Therapeutics State Government Solutions LLC multi-state initiative, TOP\$<sup>SM</sup> - The Optimal PDL \$olution<sup>SM</sup>, will review the products and therapeutic classes found on the attached list and also located on the TOP\$ webpage.

The states currently participating in TOP\$<sup>SM</sup> are Connecticut, Idaho, Louisiana, Maryland, Nebraska, Washington, and Wisconsin. **Effective April 1, 2026, the state of New Mexico will join the TOP\$ Program.** The Participation Agreement for New Mexico is currently being finalized and will be provided to Manufacturers upon execution. A new contract will begin on July 1, 2026, and will run through June 30, 2027. Supplemental rebates for the products selected by each state for its Preferred Drug List will begin to accrue **July 1, 2026**.

Louisiana and Maryland will review new products in those therapeutic classes reviewed in November 2025 that came to market and listed by First DataBank between **September 22, 2025** and **December 18, 2025**.

Please note the following:

1. Submit the TOP\$ Supplemental Rebate Offer Form through the Secure FTP site: (<https://secureftp.providersynergies.com/>).
2. TOP\$ documents referenced can be found on the Prime website: (<https://www.primetherapeutics.com/en/tops>).
3. An access bid (one of many) is required, and positioned offers are encouraged.
4. Additional offer language may be submitted directly in the Offer Form, provided it is simple, direct, and clear, as stated below.
5. Offer language on the form is limited to 220 characters (including spaces).
6. **IMPORTANT TO NOTE:** Manufacturers are required to use **simple, direct, and clear** offer language that Participating Medicaid States, invoicing teams, operational teams, and others can understand (do not include company abbreviations for drugs or for drug classes). **Non-compliant language will be rejected.**
  - For guidance on compliant language, please refer to the attached *TOP\$ Offer Language Guidance* resource.

Manufacturers are reminded that all pricing submitted will be considered “**BEST and FINAL.**” As stated on the offer form, submitted offers are binding. Final pricing (submitted through the FTP site) is due to Prime Therapeutics by **5 P.M. Eastern Standard Time** on **Friday, January 16, 2025.**

- For detailed written instructions on how to access and upload your Offer Form to the Secure FTP site, please refer to the attached *TOP\$ Offer Form Instructions* or contact Cole Anderson ([cole.anderson@primetherapeutics.com](mailto:cole.anderson@primetherapeutics.com)) for additional support. Requests for new usernames and passwords, or requests to re-set existing usernames and passwords may also be submitted by e-mail to Nicole Robinson ([nicole.robinson@primetherapeutics.com](mailto:nicole.robinson@primetherapeutics.com)). Usernames and passwords will not be provided over the telephone.
- Clinical data pertinent to the products for these reviews may be submitted to Provider Synergies in electronic format only to the attention of Maryam Tabatabai, PharmD via e-mail ([maryam.tabatabai@primetherapeutics.com](mailto:maryam.tabatabai@primetherapeutics.com)).
- Please direct all other questions concerning TOP\$ to Prime PDL Leadership ([primepdlleadership@primetherapeutics.com](mailto:primepdlleadership@primetherapeutics.com)).